Barclays PLC Acquires 95,374 Shares of Edwards Lifesciences Corporation $EW

Barclays PLC lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 8.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,291,425 shares of the medical research company’s stock after purchasing an additional 95,374 shares during the quarter. Barclays PLC owned 0.22% of Edwards Lifesciences worth $100,434,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. True Wealth Design LLC lifted its position in Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Rakuten Securities Inc. grew its stake in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock worth $29,000 after buying an additional 302 shares in the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock worth $29,000 after buying an additional 164 shares during the last quarter. Steigerwald Gordon & Koch Inc. bought a new position in shares of Edwards Lifesciences in the 3rd quarter worth $30,000. Finally, Strengthening Families & Communities LLC purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $34,000. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,370,184.06. The trade was a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $85.93, for a total transaction of $974,446.20. Following the transaction, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. The trade was a 34.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 79,144 shares of company stock worth $6,685,688. 0.34% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

EW stock opened at $81.71 on Monday. The firm’s 50-day moving average price is $82.56 and its two-hundred day moving average price is $81.47. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.89. The stock has a market capitalization of $47.46 billion, a price-to-earnings ratio of 44.65, a PEG ratio of 2.13 and a beta of 0.93. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group set a $87.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, December 17th. UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Citigroup reiterated a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research report on Thursday, December 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.